Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo

被引:43
|
作者
Schwock, Joerg [2 ]
Pham, Nhu-An [1 ]
Cao, Mary P. [1 ]
Hedley, David W. [1 ,2 ]
机构
[1] Univ Toronto, Ontario Canc Inst, Princess Margaret Hosp, Div Appl Mol Oncol,Dept Med Biophys, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada
基金
加拿大健康研究院;
关键词
Hsp90; geldanamycin; ansamycin; pharmacodynamics; xenograft;
D O I
10.1007/s00280-007-0522-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Heat shock protein 90 (Hsp90) is a conserved chaperone involved in crucial signaling events in normal and malignant cells. Previous research suggests that tumor cells are particularly dependent on Hsp90 for survival as well as malignant progression. Hsp90 inhibitors which are derivates of the natural compound geldanamycin, such as the orally bioavailable 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), are currently being tested in clinical trials and small molecule inhibitors are in development. In this study we investigated the response of a panel of cervical carcinoma cell lines in vitro and in vivo to determine potential factors that might influence the sensitivity towards Hsp90 inhibition. Methods Cell viability, proliferation and drug-induced changes on Hsp90 chaperoned "client" factors were examined with focus on G2/M cell cycle regulators, and a comparison with immortalized and normal keratinocytes was performed. ME180 and CaSki cells were grown as subcutaneous xenografts in mice treated with 6-10 mg/kg 17-DMAG by oral gavage 2x/day on a chronic schedule. Tissue concentrations of 17- DMAG were measured by high performance liquid chromatography. Results Cell death during abnormal mitosis was observed within 48 h after treatment start. ME180 and CaSki showed more cell death at this time point than SiHa and HeLa, and higher levels of pre-treatment Akt activity. IC50 values ranged between 17 and 37 nanoM geldanamycin (MTS). Keratinocytes were at least as sensitive as carcinoma cells. All cell lines responded with an increase of the G2/M fraction. Despite in vitro effectiveness and tissue concentrations of 1 mu M, only a limited tumor growth reduction was observed with 17- DMAG given close to the maximum tolerated dose level. Lower levels of Hsp90 protein, a lower Akt activity and signs of tissue hypoxia were observed in xenografts compared to cell cultures. Conclusions We show here that Hsp90 inhibition effectively induces apoptosis and growth arrest in cervical carcinoma cells in vitro. Mitotic catastrophe was identified as one mechanism of cell death. In contrast, a limited efficacy of 17- DMAG was observed in subcutaneous xenograft models. Induction of a heat shock response has previously been implicated in resistance towards Hsp90 inhibition. Additional factors might be (1) an altered abundance and/or activity of primary (Hsp90) and secondary (e. g., Akt) target(s), (2) a narrow therapeutic range of 17- DMAG by oral application and (3) response-modifying factors within the tumor environment. The further development of synthetic Hsp90 inhibitors with increased therapeutic window is warranted.
引用
收藏
页码:669 / 681
页数:13
相关论文
共 50 条
  • [41] Comparison of the activity of three different HSP70 inhibitors on apoptosis, cell cycle arrest, autophagy inhibition, and HSP90 inhibition
    Budina-Kolomets, Anna
    Balaburski, Gregor M.
    Bondar, Anastasia
    Beeharry, Neil
    Yen, Tim
    Murphy, Maureen E.
    CANCER BIOLOGY & THERAPY, 2014, 15 (02) : 194 - 199
  • [42] Irradiation plus Hsp90 inhibition: Induction of immunomodulatory anti-tumor effects
    Ernst, A.
    Kapfhammer, H.
    Zuchtriegel, G.
    Uhl, B.
    Reichel, C.
    Winssinger, N.
    Belka, C.
    Lauber, K.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2015, 191 : S71 - S72
  • [43] Hsp90 Inhibition: A Promising Therapeutic Approach for ARSACS
    Nethisinghe, Suran
    Abeti, Rosella
    Kesavan, Maheswaran
    Wigley, W. Christian
    Giunti, Paola
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (21)
  • [44] Inhibition of HSP90 molecular chaperones: moving into the clinic
    Garcia-Carbonero, Rocio
    Carnero, Amancio
    Paz-Ares, Luis
    LANCET ONCOLOGY, 2013, 14 (09): : E358 - E369
  • [45] Hsp90 Inhibition Decreases Mitochondrial Protein Turnover
    Margineantu, Daciana H.
    Emerson, Christine B.
    Diaz, Dolores
    Hockenbery, David M.
    PLOS ONE, 2007, 2 (10):
  • [46] Inhibition of the oncogenic protein hsp90 by dietary quinones
    Losso, Jack N.
    Truax, Robert E.
    Finley, John
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237 : 121 - 121
  • [47] Inhibition of HSP90 by triptolide (TPL) augments Bortezomib-induced U266 cells apoptosis
    Shen, Dan
    Tong, Xiangmin
    Zhang, Junyu
    Zhang, Panhan
    Jin, Jie
    Gao, Xiangli
    Ma, Chengjian
    JOURNAL OF MEDICINAL PLANTS RESEARCH, 2011, 5 (08): : 1429 - 1434
  • [48] Mechanistic studies on Hsp90 inhibition by ansamycin derivatives
    Onuoha, S. C.
    Mukund, S. R.
    Coulstock, E. T.
    Sengerova, B.
    Shaw, J.
    McLaughlin, S. H.
    Jackson, S. E.
    JOURNAL OF MOLECULAR BIOLOGY, 2007, 372 (02) : 287 - 297
  • [49] Exploring alternate modes of Hsp90 inhibition with peptides
    Gavenonis, Jason
    Kritzer, Joshua A.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
  • [50] Exploring alternate modes of Hsp90 inhibition with peptides
    Gavenonis, Jason
    Kritzer, Joshua A.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246